about
Rectal route in the 21st Century to treat childrenDevelopment of a model for robust and exploratory analysis of the rodent brief-access taste aversion data.Physical and microbiological stability of an extemporaneous tacrolimus suspension for paediatric use.Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations.Modeling the physiological factors that affect drug delivery from a nipple shield delivery system to breastfeeding infants.The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2 - the pilot version.Characterising the disintegration properties of tablets in opaque media using texture analysis.Specific aspects of gastro-intestinal transit in children for drug delivery design.Demonstrating evidence of acceptability: the "catch-22" of pediatric formulation development.Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients.Formulation factors affecting acceptability of oral medicines in children.Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.Patient centric formulations for paediatrics and geriatrics: Similarities and differences.Non-human tools for the evaluation of bitter taste in the design and development of medicines: a systematic review.Quality and clinical supply considerations of Paediatric Investigation Plans for IV preparations-A case study with the FP7 CloSed project.Public engagement workshop: how to improve medicines for older people?The STEP (safety and toxicity of excipients for paediatrics) database. Part 1-A need assessment study.The STEP database through the end-users eyes--USABILITY STUDY.Short term stability of pH-adjusted lidocaine-adrenaline epidural solution used for emergency caesarean section.Are extracorporeal membrane oxygenation circuits that are primed with plasmalyte and stored a likely source of infection?Colonic delivery of sodium butyrate via oral route: acrylic coating design of pellets and in vivo evaluation in rats.Inappropriate oral formulations and information in paediatric trials.Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules.Comparative bioavailability study in dogs of a self-emulsifying formulation of progesterone presented in a pellet and liquid form compared with an aqueous suspension of progesterone.Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System.Administration of melatonin mixed with soft food and liquids for children with neurodevelopmental difficulties.A wet-primed extracorporeal membrane oxygenation circuit with hollow-fiber membrane oxygenator maintains adequate function for use during cardiopulmonary resuscitation after 2 weeks on standby.Gastrointestinal transit of pellets in rats: effect of size and density.Acceptability of orodispersible films for delivery of medicines to infants and preschool children.'Formulating better medicines for children' - setting the pace for the future.Microbiological tests on oral pediatric medicines--requirements for an improved pharmacopoeia monograph.Paediatric drug deliveryMinitablets: New Modality to Deliver Medicines to Preschool-Aged ChildrenPoor Preservation Efficacy Versus Quality and Safety of Pediatric Extemporaneous LiquidsFormulating better medicines for children—reflectionsAssessment of liquid captopril formulations used in childrenFormulating better medicines for children—Still too far to walk‘Formulating better medicines for children’ – The leap forwardEuropean Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary—Formulating better medicines for childrenSmall-scale characterization of wet powder masses suitable for extrusion-spheronization
P50
Q27021942-15965340-75C2-4D6A-A713-C31869A532C0Q30885914-84DBF8C5-84A7-4F6C-9140-6DAF189D396AQ33240912-1158561E-EBF3-4A48-A33B-8F53C9C98B3CQ34410837-11614730-63AE-4937-AC9C-A65B7DA30650Q34915940-5CD89494-B6BC-4191-9002-E2B8BB16EE8AQ35000263-B587525E-5BD4-48B0-8EFC-DCFCB44BBDDBQ35581821-D9A08F83-911B-44A3-80A9-A8F39DD1E9CFQ37755611-074D98C1-1C4B-47D1-BB24-161802FA0218Q38124682-80303181-92CA-4AF6-A5E1-A374434178D7Q38194840-24F36D63-704A-4669-B40E-0AD5A8AF7690Q38469917-BE341DA1-EB42-4DFD-8EF0-A2D705548CFDQ38545613-1AE8A446-D04B-4128-ADF2-8A60626017BDQ38774707-75206F31-3FFB-496E-9D2C-488E001E383BQ38848316-91DEB2A0-F272-4ADD-ADD9-B078E5CC6F9AQ38876036-1F05EAE1-6CFD-4FC1-B886-AB1A2E67C88BQ39260190-ABE6B945-FF3C-4BA6-A057-AE8EE4AED019Q39617781-F2462F36-C7CB-4382-AE63-F294DAE24386Q40790945-3951F139-752C-47D0-8B12-370C612D123FQ42004758-A721EF81-1A59-4603-97D0-468AD5E18C9DQ42338538-3C775CEE-47DC-4B42-B6F8-3FFBA52FE625Q43801960-15878DEB-6262-469A-A2A3-E7309A4E426DQ43808330-36641647-7AB7-4C8B-9107-7FBD94B92F98Q44148238-985DEB0B-1143-49AC-8B68-1F7D2BA3564FQ44881569-43F0B14C-7635-4874-9CF3-5D3C1DE8417FQ46305200-F4A3D30B-F9B5-4304-AFC9-6F59C9BA0A4DQ46405898-D0A4C1FA-1D5D-4DFB-91E8-142715121389Q46589070-8D86B035-4BEB-4DDE-AD80-BE612B74A139Q47269274-22A7FBD6-A81F-4B7E-9895-53C49F342CD8Q48150303-1DFCDE93-24BE-4F97-9BC3-C1667D74E1B7Q51368654-717EA810-1514-4018-B110-0908EC74D654Q54625849-CADE7CC9-6DF2-4611-9FC8-39EA09927D2DQ57273969-0D38CEEE-EE86-4A53-A590-614979327F19Q57273991-6F6F250F-D7FF-4787-B969-ABF0BAFEF4A6Q57274002-160D33D8-6764-43EC-890A-191F991C73BBQ61037683-1B9C9ED4-4DFB-4FD5-9BC2-F4D44F175C9EQ61850744-32B19247-D832-4906-87D4-2C4D582765FCQ62640039-1BF87957-A5D4-4B4C-B3C9-E379F6B84D92Q62640049-B15D10F8-43E1-4279-BE60-464FF60A040AQ62640067-DD5B6CD8-4194-4551-A04E-C9F9102519FCQ77756693-321180B8-9D07-494C-9970-A111CC6266A0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Catherine Tuleu
@ast
Catherine Tuleu
@de
Catherine Tuleu
@en
Catherine Tuleu
@es
Catherine Tuleu
@fr
Catherine Tuleu
@nl
type
label
Catherine Tuleu
@ast
Catherine Tuleu
@de
Catherine Tuleu
@en
Catherine Tuleu
@es
Catherine Tuleu
@fr
Catherine Tuleu
@nl
prefLabel
Catherine Tuleu
@ast
Catherine Tuleu
@de
Catherine Tuleu
@en
Catherine Tuleu
@es
Catherine Tuleu
@fr
Catherine Tuleu
@nl
P106
P21
P31
P496
0000-0001-8384-357X